pone.0263095.g002.tif (206.11 kB)
Download file

Trends in the days of antipseudomonal agent (piperacillin–tazobactam, cefepime, and cefozopran) therapy per 100 patients, by month, during Phase 2 of the intervention period.

Download (206.11 kB)
posted on 2022-01-25, 18:37 authored by Naoya Itoh, Nana Akazawa, Eri Kanawaku, Hiromi Murakami, Yuichi Ishibana, Daichi Kawamura, Takanori Kawabata, Keita Mori, Eiichi N. Kodama, Norio Ohmagari

Each dot refers to the days of antipseudomonal agent therapy per 100 patients in each month, and the slope is based on linear regression in the two phases. The explanation of each phase is as follows: Phase 1 (antimicrobial notification by the infection control team from April 1, 2018, to March 31, 2020); Phase 2 (establishing an infectious disease [ID] consultation service and implementation of the Antimicrobial Stewardship Program [ASP] from April 1, 2020, to March 31, 2021). The level of the monthly DOT of the three antipseudomonal agents did not decrease (coefficient: 0.20; 95% confidence interval [CI]: −0.67 to 1.09, p = 0.65), although the trend decreased (coefficient: −2.22; 95% CI: −0.33 to −0.10, p<0.001).